Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study.
Mark F H Brougham, Patricia M Crofton, Emma J Johnson...
https://pubmed.ncbi.nlm.nih.gov/22472563/Actively Recruiting
Led by Erasme University Hospital · Updated on 2026-08-12
275
Participants Needed
8
Research Sites
782 weeks
Total Duration
This research aims to evaluate the Antimfcllerian Hormone AMH as a predictor of infertility risk in children with cancer or benign diseases treated with chemotherapy andor pelvic irradiation. It focuses on girls aged 3 to 14 years, including prepubertal and pubertal patients, who are classified into high, moderatelow, and no risk groups based on their treatments potential impact on ovarian reserve. The study addresses the challenge of assessing ovarian reserve and fertility preservation needs in young patients who progress normally through puberty but may have impaired ovarian function due to treatment. Participants are observed over several years with no intervention administered as part of the study. They are grouped by their risk category high risk those receiving conditioning therapy for bone marrow transplantation or pelvic irradiation, moderatelow risk patients treated with chemotherapy regimens associated with varying risks, and no risk patients with benign or malignancies not involving gonadotoxic treatment. Assessments include measuring AMH levels and other hormones before and after treatment and during follow-up visits up to 18 years old. During the study, participants undergo evaluations at inclusion, end of treatment, annually for the first three years, and then every two years until age 18. These include blood tests for ovarian reserve hormones AMH, FSH, estradiol, testosterone, LH, pubertal stage assessments using TANNER criteria, menstrual cycle monitoring, and bone age evaluation via X-rays. Researchers will use these measurements to identify patients at risk of premature ovarian failure and to better understand how chemotherapy affects ovarian function in relation to pubertal status.
CONDITIONS
AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)
I
Isabelle Demeestere, PhD
J
Julie Dechene
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Erasme University Hospital
Lead Sponsor
Queen Fabiola Children's University Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - From inclusion until participants reach 18 years old
Participants undergo blood tests to measure hormone levels, pubertal assessments, menstrual cycle monitoring, and bone age X-rays at scheduled intervals to evaluate ovarian reserve and function over time.
At inclusion, end of treatment, yearly for first 3 years, then every 2 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Mark F H Brougham, Patricia M Crofton, Emma J Johnson...
https://pubmed.ncbi.nlm.nih.gov/22472563/W Hamish B Wallace, Alice Grove Smith, Thomas W Kelsey...
https://pubmed.ncbi.nlm.nih.gov/25130994/Isabelle Demeestere, Philippe Simon, Laurence Dedeken...
https://pubmed.ncbi.nlm.nih.gov/26062556/R Imbert, F Moffa, S Tsepelidis...
https://pubmed.ncbi.nlm.nih.gov/24958067/Erasme University Hospital
Lead Sponsor
Queen Fabiola Children's University Hospital
Collaborating Sponsor